CBIO vs CGEM: fair value comparison
Crescent Biopharma, Inc. and Cullinan Therapeutics, Inc. · Updated 2026-10-19
CBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CGEM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CBIO currently ranks higher by quality score.
| CBIO | CGEM | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.84 | $12.93 |
| 12-month range | $8.94–$26.98 | $7.19–$22.95 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #226 of 301 Healthcare | #228 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: CBIO fair value analysis · CGEM fair value analysis